Full Press Release Details
Celcuity Announces Appointment of Richard Buller to Board of
Minnesota December 5, 2019 Celcuity Inc. (NASDAQ:
CELC) a functional cellular analysis company that is discovering
new cancer subtypes and commercializing diagnostic tests designed
to significantly improve clinical outcomes of cancer patients
treated with targeted therapies, today announced the appointment of
Richard Buller, M.D., Ph.D. to Celcuity's Board of Directors,
effective December 3, 2019.
are very pleased to have attracted Dr. Richard Buller, a proven
oncology drug development leader, to join our Board.
Richard's experience leading oncology clinical development
and translational medicine departments at major pharmaceutical
companies will provide a valuable perspective to Celcuity. He has
participated in the development of 15 drugs and several companion
diagnostics that received U.S. FDA approval, giving him a broad
perspective that is very relevant to Celcuity, said Brian F.
Sullivan, Chairman and Chief Executive Officer of
Buller most recently served as Head Oncology Clinical Development
and Vice President of Translational Oncology at Pfizer, Inc., one
of the world's largest pharmaceutical companies, until he
retired in 2016. He had previously served as Vice President of
Translational Medicine at Exelixis, a leading biopharmaceutical
company, where he led efforts to study patients selected by
molecular testing for inclusion in their phase 2 and phase 3
clinical trials. He began his pharmaceutical company career at
GlaxoSmithKline as Director of the Oncology Medicine Development
Center. Prior to his leadership positions in drug development, he
was Professor of Gynecologic Oncology at the University of Iowa,
where he led laboratory research focused on identifying genomic
variants involved in ovarian cancer. He received his M.D. from the
Baylor College of Medicine, where he also received his Ph.D. in
Celcuity is a functional cellular analysis company that is
discovering new cancer subtypes and commercializing diagnostic
tests designed to significantly improve the clinical outcomes of
cancer patients treated with targeted therapies.
Celcuity's proprietary CELx diagnostic platform uses a
patient's living tumor cells to identify the specific
abnormal cellular activity driving a patient's cancer and the
targeted therapy that can best treat that patient's disease.
Celcuity is headquartered in Minneapolis, Minnesota. Further
information about Celcuity can be found at www.celcuity.com.
Forward-Looking Statements
This press release contains statements that constitute
forward-looking statements, including the anticipated
benefits to the clinical outcomes of cancer patients.
Forward-looking statements are subject to numerous conditions, many
of which are beyond the control of Celcuity, which include, but are
not limited to, those set forth in the Risk Factors section of
Celcuity's Annual Report on Form 10-K for the year ended
December 31, 2018. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. Celcuity undertakes no obligation to update
these statements for revisions or changes after the date of this
release, except as required by law.
Sullivan, bsullivan@celcuity.com
Hahne, vhahne@celcuity.com